The notion the article's timing was by design to complement forthcoming Rexlemestrocel announcements or NEJM news is delicious; regardless, it's demonstrative of the appealing narrative for the first mobs to get those FDA ticks of approval.
"Hey people who want/need stem cells therapies, here's a supplier you can trust - by the way, not only are your other options a bunch of cowboys, we're actively trying to close them down".
The notion the article's timing was by design to complement...
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.025(2.29%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.10 | $1.06 | $4.942M | 4.613M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 70659 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 43531 | 2 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |